Abstract
Far-UVC, in the form of filtered Krypton-Chloride lamps, is a promising technology for reducing airborne transmission of disease. Whilst significant research has been undertaken to investigate skin safety of these lamps, less work has been undertaken on eye safety. In particular, there is very limited data on human eye safety or discomfort from the deployment of this germicidal technology. In this pilot study, immediate and delayed eye discomfort were assessed in a simulated office environment with deployment of Krypton-Chloride lamps. The discomfort was assessed immediately post-exposure to the Far-UVC and several days after exposure using the validated, standardized Standard Patient Evaluation Eye Dryness (SPEED) and Ocular Surface Disease Index (OSDI) questionnaires. Our results show that there was no significant eye discomfort or adverse effects from the deployment of Far-UVC in this simulated office environment, even when the lamps were operated continuously. In addition, through collection of bacteria and fungi on agar plates, with this non-optimised lamp arrangement a statistically significant reduction in pathogens of 52% was observed. Far-UVC in this simulated office environment did not cause any clinically significant eye discomfort and was effective at reducing pathogens in the room. These results contribute an important step to further investigation of the interaction of Far-UVC with the human eye.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Science and Technology Facilities Council Impact Accelerator Account (IAA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Teaching and Ethics Committee of the University of St Andrews gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
